The APOBEC3A Knockout HeLa Polyclonal Cells provide a heterogeneous CRISPR/Cas9-mediated gene disruption model in HeLa cervical adenocarcinoma cells. This polyclonal population captures diverse genetic outcomes of APOBEC3A loss, creating a versatile platform for studying the deaminase??s roles in antiviral immunity, DNA mutagenesis, and interferon responses.
The host HeLa line is an adherent, HPV-18-positive epithelial cell model derived from cervical adenocarcinoma, widely used for cancer and virology research. Its immortalized background and intact interferon signaling machinery offer a relevant context for investigating APOBEC3A function in oncogenic and antiviral pathways.
APOBEC3A is a single-stranded DNA cytidine deaminase converting cytosine to uracil in viral genomes, retrotransposons, and occasionally host DNA. Its transcription is activated by type I interferons (IFN-??/??), which are produced via IRF3- and IRF7-mediated pathways following viral infection. Subsequent IFNAR1/IFNAR2 engagement triggers JAK1/TYK2 kinase activity, leading to STAT1/STAT2 phosphorylation. These STAT proteins heterodimerize with IRF9 to form ISGF3, which binds ISRE in the APOBEC3A promoter. The enzyme interacts with replication factors RPA and PCNA to access ssDNA substrates, while UNG participates in repairing resultant uracil lesions. In HIV infection, APOBEC3A deaminates viral cDNA, inducing hypermutation and restriction, a process countered by the Vif accessory protein.
In HeLa cells driven by HPV-18, APOBEC3A knockout enables dissection of its dual host-defense and mutagenic roles. Researchers can examine whether APOBEC3A restricts HPV replication or contributes to genomic instability underlying cervical carcinogenesis. The model permits analysis of interferon-stimulated APOBEC3A induction and its impact on viral infectivity and mutation accumulation, connecting upstream STAT1?CSTAT2?CIRF9 signaling to downstream DNA modification and repair processes.
The knockout cells support diverse experimental workflows, including biochemical deaminase activity assays, qRT-PCR gene expression analysis, and protein-level detection via western blot or immunofluorescence. Mutation sequencing enables characterization of APOBEC3A-dependent hypermutation signatures in both genomic and viral DNA, while lentiviral infectivity assays provide a direct functional readout of viral restriction. Interferon treatment followed by flow cytometry facilitates dynamic profiling of innate immune signaling in the absence of APOBEC3A activity. For further inquiries or technical specifications, please contact Ascent Research.
